Phosphate Production Recovery and 2026 Guidance
Produced 1.7 million tonnes of phosphate in Q4 2025 (despite an extended Bartow turnaround); company expects at least 7.0 million tonnes of phosphate production in 2026 with upside as operating factors normalize.
Potash Production Strength
International potash sales set a record in 2025; Esterhazy returned to full operating rates and HydroFloat is ramping. Mosaic expects to produce around 9 million tonnes of potash in 2026 (similar to 2025) and anticipates record Esterhazy output.
Material Cost and Efficiency Improvements
Delivered $150 million of cost savings in 2025 ahead of schedule and targets an additional $100 million of savings in 2026 through technology-enabled initiatives, supply chain optimization and supplier consolidation.
Improved Phosphate Conversion Cost
Fourth quarter phosphate cash cost of conversion was $112 per tonne — roughly $20 per tonne improvement from an earlier high watermark in 2025; management expects further structural declines with scale (targeting below $100 conversion cost over time).
Potash Cash Cost Competitiveness
Reported 2025 potash cash cost of production averaged $75 per tonne and would have met Analyst Day target range if not for higher-cost Colonsay extension.
Brazil Operations and Rock Cost Progress
Brazil rock output reached near-record levels in 2025; Mosaic Fertilizantes blended rock cost per tonne fell to $97 (lowest since 2021). Completed a 1 million tonne blending facility in Palmeirante to expand distribution capacity.
Mosaic Biosciences Rapid Growth
Mosaic Biosciences doubled net sales to $68 million in 2025, reached 60+ registrations and sales in 16 countries; management expects another year of doubling net sales in 2026 with 8–10 new product launches, and gross margins in the 40s.
Portfolio Reallocation and Monetization Progress
Divested several noncore assets (Patos de Minas, Taquari) and a pending Carlsbad sale; transactions announced in 2025 expected to generate approximately $170 million in proceeds and reduce ARO by ~$60 million. Ma'aden equity position valued at about $2.1 billion.
Working Capital Release Potential
Management estimates a $300 million to $500 million working capital release in 2026 driven by inventory drawdown (including ~240,000 tonnes excess phosphate rock, ~ $140 million at current values) and demand recovery, which should materially improve cash flow.
Capital Expenditure Path and Near-Term Investment
2026 CapEx expected around $1.5 billion (higher than 2025 due to gyp stack and clay settling area projects); management views this as a near-term peak and expects CapEx to trend down toward ~$1.0 billion by 2030.